ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Anavex Life Sciences Corporation

Anavex Life Sciences Corporation (AVXL)

4.21
0.13
(3.19%)
Closed 25 June 6:00AM
4.21
0.00
( 0.00% )
Pre Market: 6:01PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
4.21
Bid
3.54
Offer
4.60
Volume
-
0.00 Day's Range 0.00
3.25 52 Week Range 10.45
Market Cap
Previous Close
4.21
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
1,204,901
Shares Outstanding
84,641,537
Dividend Yield
-
PE Ratio
-7.50
Earnings Per Share (EPS)
-0.56
Revenue
-
Net Profit
-47.51M

About Anavex Life Sciences Corporation

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are u... Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Carson City, Nevada, USA
Founded
1970
Anavex Life Sciences Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AVXL. The last closing price for Anavex Life Sciences was US$4.21. Over the last year, Anavex Life Sciences shares have traded in a share price range of US$ 3.25 to US$ 10.45.

Anavex Life Sciences currently has 84,641,537 shares in issue. The market capitalisation of Anavex Life Sciences is US$356.34 million. Anavex Life Sciences has a price to earnings ratio (PE ratio) of -7.50.

AVXL Latest News

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

Anavex Life Sciences Announces Expansion of Leadership Team

NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire NEW YORK, May 10, 2024 NEW YORK, May 10...

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders PR Newswire NEW YORK, May 7, 2024 NEW YORK, May 7, 2024...

Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
10.4913.17204301083.724.313.633722147524.0568403CS
40.153.694581280794.064.313.5113675093.96391144CS
12-0.5593-11.72708783264.76934.793.2512049014.01104579CS
26-4.87-53.63436123359.0810.0663.2513404205.06789698CS
52-3.91-48.15270935968.1210.453.2511499926.0734427CS
156-21-83.300277667625.2131.53.25120957810.99166702CS
2600.9629.53846153853.2531.52.2126353910.49663263CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
OAROAR Resources Limited
AUD 0.002
(100.00%)
1.25M
VN8Vonex Ltd
AUD 0.035
(94.44%)
19.76M
MTLMantle Minerals Limited
AUD 0.003
(50.00%)
34.24M
ALRAltair Minerals Ltd
AUD 0.004
(33.33%)
25k
EDEEden Innovations Ltd
AUD 0.002
(33.33%)
6.03M
TD1Tali Digital Limited
AUD 0.001
(-50.00%)
75.66k
ABEAustralian Bond Exchange Holdings Ltd
AUD 0.013
(-35.00%)
163.72k
BFCBeston Global Food Company Limited
AUD 0.002
(-33.33%)
450.29k
CLZClassic Minerals Limited
AUD 0.001
(-33.33%)
354.1k
PRXProdigy Gold NL
AUD 0.002
(-33.33%)
30.72k
PURPursuit Minerals Limited
AUD 0.0025
(-16.67%)
57.15M
TM1Terra Metals Ltd
AUD 0.079
(8.22%)
54.93M
REDRed 5 Limited
AUD 0.385
(-6.67%)
51.09M
88E88 Energy Limited
AUD 0.002
(0.00%)
42.68M
MTLMantle Minerals Limited
AUD 0.003
(50.00%)
34.24M

AVXL Discussion

View Posts
Investor2014 Investor2014 1 hour ago
My opinion remains unchanged in that only an actual CHMP validated MAA filing that subsequently survives the EMA process clock-stop 1 would significantly improve the $AVXL price. Surviving clock-stop 1 is the hardest per the EMA published stats.

We can always hope that the July 28th AAIC presentation moves the needle. I also still have a sense that the AAIC presentation may mean no peer review published. If that turns out to be the case and the market waited in vain for the peer review 'catalyst', then only the MAA filing and its progress can help the price of $AVXL. Starting new trials is great, but will represent more cost for several years without revenue insight.

Let's see, I may well be too sceptical.
👍️ 1
k9uwa k9uwa 1 hour ago
Hi Tred Yes and No. One can have a "Ham Radio Station" for a few hundred bucks. Or for considerably more bucks one can have a competitive "contest station." I built this station back in 1989 as a competitive "contesting station" Back then sometimes I operated the station as a "Single Operator" or as a "multi opreator" in long haul DX contests. Today usually my station is used by a younger Ham Radio friend of mine. In these contests I get the notoriety as "Station Owner" and Mike my "Hired Gun" operator gets his share of wins in the long haul contests. As to me operating my Ham Radio Station? 8 months or so of the year I operate it "Remotely" Yes an internet connection between ME wherever I might be with broadband internet and the station. For me the ancient analog type a real project to learn to setup and operate my station "remotely". So yes today I run the ham station with a laptop computer from wherever I might be... usually far south during the winter.

Back to Anavex. I do think we are approaching the "Finish Line" for approval of 2-73 and probably one of these days 3-71perhaps is better than 2-73.

John k9uwa
👍️0
k9uwa k9uwa 2 hours ago
"You served in Korea?" Yes 1966-early 1968. I lived in Seoul S Korea. My ham radio callsign while I was there HL9KW. The "Kilowatt Watt" station from Seoul S Korea. Primary MOS was Saxophone player in an Army Band. secondary MOS if the you know who jumped the DMZ was Semi-Truck driver because yes I knew how to drive anything with rubber tires. I was really pissed off when only two weeks or so back home discharged from Uncle's Army the Pueblo incident and the attempt on the S Korean Prez happened. Wishing I had still been there. Many times while I was there I was relieved of duty to the band to run Phone Patches "telephone by ham radio" calls for our troops back to the US. Explanation .. Ham Radio contact from Korea back to USA and telephone from whoever we made good solid contacts with in the US back to friends relatives of the GI. I probably can't say today what was in the Trailer assigned to me to pull if U know who jumped the DMZ. Yet today I do like some types of Kimchi. But Adrian Cronauer many times back then listened to him on AFKN and yet today enjoy YouTube replays. "Good Morning "you know what comes next" We have a group of us Mil Musicians and an annual "Reunion" and I usually attend that function.
John k9uwa
👍️0
Cpap21 Cpap21 2 hours ago
What will a good peer review do for our stock price immediately?
And it always seems like we are on the verge of finally seeing our investment payoff. Are we actually close or as some believe — is the can being kicked down the road still?
Just asking !!
👍️0
sage4 sage4 3 hours ago
Powerwalker, For the peace, everyone has freedom of speech and we are on a free message board.
His “Have been here since 2015……..” is just like your “ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!” No personal attack intended.
🏁 1 👍️ 2
tredenwater2 tredenwater2 4 hours ago
Very nice John, looks like quite the expensive hobby!
👍️0
bb8675309 bb8675309 4 hours ago
Dude, I am never going to complain about my cable bill again. 🔌
👍️ 1
ignatiusrielly35 ignatiusrielly35 5 hours ago
You served in Korea? I know it’s a different genre (and war) but did you ever run into Adrian Cronauer?
👍️0
k9uwa k9uwa 6 hours ago
You’re a Ham? Thank you for your service. Yes I am. Welcome to my backyard Ham Radio Antenna system.


Yes that is me in the mancage along with one of Fruchey's iron workers.
John k9uwa
👍️ 3 👏 1
ignatiusrielly35 ignatiusrielly35 6 hours ago
You’re a Ham? Thank you for your service.
🏁 1 👍️ 1
k9uwa k9uwa 6 hours ago
please stop the "2015" every time you post?

Powerwalker I promise never to mention that year again. I am anything but a negative poster. I do think we are finally in the Home Stretch.
The Finish Line is within sight! 🏁 I don't hide behind a moniker. Put me into your favorite search engine.

John k9uwa
🆖 1 🍼 1 👍️ 2 👏 1
kspar1 kspar1 6 hours ago
RE: ADL and early AD treatment... I've been told that the only two means of AD diagnosis are written/verbal memory/pattern tests and a brain scan.
I assume the latter is not supportive of an early stage AD situation since it's looking for visible damage (right?). If this is the case, then, once FDA/EMA approved, doesn't Anavex need to ride the coat tails of a decent set of diagnostic AD tools going forward? A venture capital friend laughed at me when I told him about AVXL long ago. He had funded and continues to work with a bioTech firm focused exclusively on an AD diagnostic that's keying off of immune system indicators. His point was "won't your drug be a lot more effective and wanted if it can begin work at Stage 1 rather than Stage 12? Like Falconer said, the ADL factor is less of a factor in those early stages.

Guess what I'm trying to say, "won't the AVXL story be more of a market success if there are decent diagnostic strategies that make it possible to treat the earliest of AD stages?" As an investor, that seems to me to be part of the equation. I don't recall a discussion on this topic. As a concerned husband, I hope somebody will point me to successful AD determination strategies... more that a damn "draw this, remember that" test. Thx!
🎯 1 🏁 1 🏆️ 1 👍️ 1
ignatiusrielly35 ignatiusrielly35 7 hours ago
Sarc. Asm.
👍️0
boi568 boi568 7 hours ago
What?
👍️ 1
bas2020 bas2020 7 hours ago
There is obviously a "sweet spot" in the AD progression where ADL improvements with treatment are demonstrative, as seen by the O.R. calculation, where a group of strong responders (>4x the placebo patients) exceeded an improvement threshold. It just couldn't show stat sig for the means comparison. Evidently, O.R. was part of the SAP for Anavex to initially claim that all endpoints were met.
👍️ 5 👏 2
ignatiusrielly35 ignatiusrielly35 7 hours ago
Good God. You’ve really sold out with you regurgitation of these superficial bashing points. All because you want your covered calls to expire. Pretty pathetic.
🏆️ 2 👍️ 6 👏 1 💯 1 🤺 1
ignatiusrielly35 ignatiusrielly35 7 hours ago
You keep bringing up these details. Please stop.
👎️ 1 💩 1 🤡 1 🧻 1
WolfofMia WolfofMia 8 hours ago
But you do so who cares!!!
🆖 1 🍼 1 🏁 1 👍️ 2 🤣 3
Steady_T Steady_T 8 hours ago
More likely with his consulting for so many different companies, he doesn't want to jeopardize his relationships by owning stock in a particular company. For him to own stock in a potential competitor would raise serious questions about information flow.
🆖 2 🍼 1 🏁 1 👍️ 6
Investor2014 Investor2014 8 hours ago
He doesn’t believe enough in Anavex to own Shares, hmmm!
🐀 2 👍️ 1 👺 1 💩 1 🤡 2 🦨 1
Steady_T Steady_T 8 hours ago
We'd all like to have approval tomorrow morning. Alas, that is not the system that Anavex has to deal with.

Remember that Anavex has multiple shots on goal. It only needs to score once. All goals after that are icing on the cake.
🆖 1 🍼 1 👍️ 4
powerwalker powerwalker 8 hours ago
nidan, please cut the Dr. Peter Senge remarks. You don't need quoting him for years and its relevance is ... IRRELEVANY!!

Peace,
John
🆖 1 🍼 1 👎️ 1 💩 2 🤡 1 🤮 1 🦨 1
powerwalker powerwalker 8 hours ago
I called and LM for Clint as to where was the PR after DM's comments about Rett's new trail that would be announced at Rett conference last week.

No reply.
🆖 1 🍼 1 🏁 1 👍️ 1
nidan7500 nidan7500 9 hours ago
But read the descriptions of Alzheimer's symptoms. ADLs are mentioned far down the list. Essentially, Alzheimer's diminishes cognition, the ability to think and speak, the things the three successful metrics of the blarcamesine trial excelled at.

So, blarcamesine will not be intended to target or treat patients with advanced stages of Alzheimer's, where the activities of daily living (ADLs) are already diminished and compromised. Just the opposite. With the number of new tests for early-stage Alzheimer's, even before any real symptoms can be perceived (the prodromal test factor --- detection before symptoms even begin to be perceived) the Anavex drug will have its greatest impact on the global Alzheimer's disease problem.

An example of progress on some learning scale to come....As Dr. Peter Senge would say..."this is an example of .."we do not know, what we do not know." IMO, this an example of learning something new.

There will likely be a lot more examples like this...and that is a good thing.
🆖 1 🍼 1 🏁 1 👍️ 5
powerwalker powerwalker 9 hours ago
THE FIRING CAN'T OCCUR SOON ENOUGH!!
🆖 1 🍼 1 🏁 1 👍️ 3 👎️ 1 💩 2 🤡 1 🤮 1 🦨 1
Steady_T Steady_T 9 hours ago
Apparently the whites of their eyes is when the OLE is completed.
🆖 1 🍼 1 🏁 1 👍️ 1
tredenwater2 tredenwater2 9 hours ago
William and Falconner with respect to the Alzheimer’s Association’s response I say who the flip cares, let them pound sand. They are irrelevant imo once Blarcasamine (the appetizer) hits the market. Just wait until 3-71 starts pivotal Frontal Lobe Dementia trials.

They are on the take for whoever has the hot ticket imo.
🆖 1 🍼 1 🏁 1 👍️ 9 👏 2 💥 5 😎 2 🤺 1 ❤️ 2
powerwalker powerwalker 9 hours ago
Would you please stop the "2015" every time you post?

NO ONE CARES ... given your persistence, it is almost seems that you are a subtle negative poster.

If it were important, my posts would have "2009" included as when we invested!

ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!

P.S. Notice, I don't include "2009" within my tag line.
🎯 1 🏆️ 1 👍️ 1 👎️ 1 💩 2 🤡 2 🤮 1
k9uwa k9uwa 9 hours ago
Alzheimer's Patients ADLs: The same with my Mother. She was allowed to stay by herself in her own home for the first 4 years or so after we knew she had Alzheimer's. I did have an experienced caretaker there at least 8 hours a day with her. Plus meals, A Nurse a couple times per week. After that my wife and I moved her into our home. And kept the caretaker and nurse as well. Her last couple years with us... sometimes I was ME... sometimes I was "My Dad" who had passed away some 15 years prior. And sometimes she would complain to my wife THAT THING YOUR MARRIED TO HE HAS TO GO. Yet some days or parts of days she was near normal as to memory as to who is who. It is a truly terrible disease. So yes no question about it ADL's for early patients make no sense at all.

Now you know why I am here. I searched all the early stage drugs back in 2015 in trial mode and picked Anavex to be the winner.
John k9uwa
🆖 1 🍼 1 🏆️ 1 👍️ 15 🤗 1 ❤️ 1
WolfofMia WolfofMia 10 hours ago
I guess Doc doesn't want to talk about it anymore.....
🆖 1 👍️ 1 💩 1 🤣 1
Hosai Hosai 10 hours ago
Was actually 0.0005 (5 in 10,000).
🆖 1 🍼 1 🏁 1 🏆️ 1 👍️ 5
boi568 boi568 10 hours ago
It turns out that determining brain volume retention in early AD was pretty easy for Anavex to spot -- with a p value of .005.
🏁 1 🏆️ 1 👍️ 7
williamssc williamssc 10 hours ago
How will the Alzheimer's Association and its members respond when they learn of these, blarcamesine's real clinical trial results?
That should be an eye opener. If we have a BP partner could see many positive comments, if not maybe just crickets.
🏁 1 👍️ 7 👏 1
Hosai Hosai 11 hours ago
Dr Sabbaghs consulting fees include Lilly, Roche and Eisai - Disclosure
Prothena Consulting Fees Self , Synaptogenix Consulting Fees Self , Alzheon Ownership Interest Self , Cognito Therapeutics Consulting Fees Self , Anavex Consulting Fees Self , Novo Nordisk Consulting Fees Self , KeiferRx Consulting Fees Self , Eisai Consulting Fees Self , NeuroTau Ownership Interest Self , NeuroTherapia Consulting Fees Self , Roche Consulting Fees Self , Lilly Consulting Fees Self , T3D Consulting Fees Self , Signant Consulting Fees Self https://alz.confex.com/alz/2024/meetingapp.cgi/Person/57340
🆖 1 🍼 1 🏁 2 👍️ 4
falconer66a falconer66a 11 hours ago
Thanks. Now have the 5 in the right column. The maximum acceptable p-value for statistical significance is 0.05, not 0.50.
🆖 1 👍️ 4 💩 1
Investor2014 Investor2014 11 hours ago
Exactly!
🏁 1 👍️ 1
Investor2014 Investor2014 11 hours ago
Make sure you don't forget important zeros.
the required p=0.50 threshold
Same tendency as Georgijjl, hmm!
🐀 1 👍️ 2 👺 1
powerwalker powerwalker 11 hours ago
I think it is the SAME GUY!


ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!
🏁 1 👍️ 1
Investor2014 Investor2014 11 hours ago
So is this guy gone?
Dr. Jin Vice President Head of Biostatistics
Surely you can't have two guys with that exact same title.
🐀 1 👍️ 1 👺 1 💩 1 🦨 1
falconer66a falconer66a 11 hours ago
The ADL Non-factor.
Wow. Greatly appreciate your insight [on the blarcamesine ADL metric....]
Thank you.

In all honesty, when I first saw that blarcamesine ADL p-value, as discrepant as it was compared to the other three, I thought that it probably disqualified the drug from ever being approved by the FDA. The other three p-values were way below the required p=0.05 threshold of statistical significance and therapeutic validity. But blarcamesine utterly failed the ADL test. The numbers don't lie.

When I first saw it I tried to figure out what this "ADL" phenomenon was. Researchers, for convenience, like to use acronyms. A lot easier to state throughout a report "ADL" instead of "activities of daily living." But retail stock equity investors don't know the language or acronyms of CNS disease research. So, I looked up the acronym.

"Activities of daily living." Being able to dress oneself, to eat, attend to personal cleanliness, etc. are all extremely important. Failure to properly attend to ADLs makes one an invalid.

But read the descriptions of Alzheimer's symptoms. ADLs are mentioned far down the list. Essentially, Alzheimer's diminishes cognition, the ability to think and speak, the things the three successful metrics of the blarcamesine trial excelled at.

So, blarcamesine will not be intended to target or treat patients with advanced stages of Alzheimer's, where the activities of daily living (ADLs) are already diminished and compromised. Just the opposite. With the number of new tests for early-stage Alzheimer's, even before any real symptoms can be perceived (the prodromal test factor --- detection before symptoms even begin to be perceived) the Anavex drug will have its greatest impact on the global Alzheimer's disease problem.

I anticipate, soon enough, that late middle age or early elderly patients will commonly be administered prodromal ("before symptoms") Alzheimer's tests. "Mrs. Smith, we have some bad news. Your test results came back and they show that you are going to come down with Alzheimer's disease. But, so fortunately, we now have a drug, blarcamesine, that will prevent the disease from progressing. Here is your prescription for the drug. It will allow you to be free of Alzheimer's symptoms in the years going forward."

How will the Alzheimer's Association and its members respond when they learn of these, blarcamesine's real clinical trial results?
🆖 1 🍼 1 🎯 7 🏁 2 👍️ 17 🙏 2
Talon38 Talon38 11 hours ago
Powerwalker....agree completely that ADL in early Alzheimer's patients is a very difficult area to measure as Falconer has discussed. It appears that the FDA thinks so also. Brain size reduction is far more indicative of the disease implication! Although, it too may be hard to determine in Alzheimer's early stages.
🆖 1 🏁 1 👍️ 8 💩 1
Investor2014 Investor2014 11 hours ago
More likely just weak, mediocre and useless pumpers not up to the job.
🐀 1 👍️ 1 👺 1 💩 1 🦨 1
sab63090 sab63090 11 hours ago
Abe:

That's why I initially asked the question about why he was not presenting, but I think you changed my mind because of the possibility of the FDA showing favor to someone once working at the FDA...they might have considered that it would not be received well....darn it!
🆖 1 💩 1
powerwalker powerwalker 11 hours ago
WHO "TF" CARES about appearances? The suffering need help NOW! Get the drug approved ... NOW!! When one is in a war, appearances don't count ... Results count!!! We are in a war ... to push nidan's refrain ... "FIRE WHEN YOU SEE THE WHITES OF THEIR EYES!!!
It is time to FIRE!!!!

ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!
🎯 1 🏁 1 🏆️ 1 👍️ 8 ❤️ 4
sab63090 sab63090 11 hours ago
Thanks, Abe....I didn't think about that: good point!
🆖 1 🏁 1 👍️ 1 💩 1
sab63090 sab63090 12 hours ago
Hi Tom!
I'm kind of watching for some sign of sustained strength/volume and I am backing away from considering additional sizable weakness, but respect the "bleeding down" opinion at this point since the decline from $31 to now has lasted for so long and the $XBI seems to be showing some investor interest after being so unloved for so long ! Many portfolio managers like to go into last year's weakest groups and the $XBI has been one for several years.

I would assume the next 2 short interest reports 6/26, 7/10 might be of some help with the last one indicating the 6/28 (re-balance date) we will need to wait until August 15th, I guess, to see how the 45 days after quarter end shakes out.....Why so long? No sensible person can explain that to me especially now that we have 1 day settlements....ha ha

Cheers, Steve
🆖 1 🏁 1 👍️ 2 💩 1
georgejjl georgejjl 12 hours ago
From the original top line results from Anavex's Phase 2b/3 trial using blarcamesine to treat early stage Alzheimer's disease:

Clinically significant response categorization in function defined as ADCS-ADL ≥ +3.5-point change from baseline

Since the range for the ADCS-ADL score is from zero to 78, then 78 is an absolute maximum ADCS-ADL score.

Therefore, since 78 is the absolute maximum ADCS-ADL score, then any trial participant with a baseline ADCS-ADL score of 78 minus 3.5= 74.5 or higher cannot possibly be considered as being classified as having a clinically significant response. Given a comparison to the Phase 2a Anavex Alzheimer’s trial, I estimate that 35 or more participants taking Blarcamesine can not be classified mathematically as having a clinically significant response for the Phase 2b/3 trial.

This can and probably is a significant number of participants that should not be ignored.

Good luck and GOD bless,
🆖 1 💩 1 🤢 1
abew4me abew4me 12 hours ago
Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics
Thu, Mar 9, 2023

https://finance.yahoo.com/news/anavex-life-sciences-appoints-former-120000992.html?fr=sycsrp_catchall
🆖 1 🍼 1 🏁 1 👍️ 5
HMB2010 HMB2010 12 hours ago
Agreed. ADL's nearly last to go in advanced stages in my experience 30+ yrs in healthcare.
🆖 1 🍼 1 👍️ 4
kspar1 kspar1 12 hours ago
Wow. Greatly appreciate your insight, not just to explain the ADL relevancy, but the possible journey one might experience (as you did).
🆖 1 🍼 1 🎯 1 🏁 1 👍️ 6

Your Recent History

Delayed Upgrade Clock